van
doremalen
n
bushmak
morri
dh
et
al
aerosol
surfac
stabil
compar
new
england
journal
medicin
hamdi
fc
donovan
jl
lane
j
et
al
outcom
monitor
surgeri
radiotherapi
local
prostat
cancer
n
engl
j
med
klotz
l
vesprini
sethukavalan
p
et
al
longterm
followup
larg
activ
surveil
cohort
patient
prostat
cancer
journal
clinic
oncolog
pisanski
tm
hunt
gomella
lg
et
al
durat
androgen
suppress
radiotherapi
local
prostat
cancer
radiat
therapi
oncolog
group
random
clinic
trial
journal
clinic
oncolog
morri
wj
tyldesley
rodda
et
al
androgen
suppress
combin
elect
nodal
dose
escal
radiat
therapi
ascendert
trial
analysi
surviv
endpoint
random
trial
compar
lowdoser
brachytherapi
boost
doseescal
extern
beam
boost
highand
intermediaterisk
prostat
cancer
intern
journal
radiat
oncolog
biolog
physic
zapatero
guerrero
maldonado
x
et
al
late
radiat
cardiovascular
advers
effect
androgen
depriv
highdos
radiat
therapi
prostat
cancer
result
dart
random
phase
trial
intern
journal
radiat
oncolog
biolog
physic
spratt
dess
r
efstathi
j
et
al
two
year
antiandrogen
treatment
increas
othercaus
mortal
men
receiv
earli
salvag
radiotherapi
secondari
analysi
nrg
oncologyrtog
random
phase
iii
trial
intern
journal
radiat
physic
summari
rad
framework
remot
visit
avoid
defer
shorten
radiotherapi
creat
appli
determin
appropri
manag
men
prostat
cancer
global
pandem
consensu
reach
aspect
patient
visit
treatment
overal
resourc
util
reduc
identifi
stage
prostat
cancer
treat
radiotherapi
purpos
global
pandem
benefit
routin
visit
treatment
cancer
patient
must
weigh
risk
patient
staff
societi
prostat
cancer
one
common
cancer
radiat
oncolog
depart
treat
effici
resourc
util
essenti
set
pandem
herein
aim
establish
recommend
framework
evalu
prostat
radiotherapi
manag
decis
rapidli
conduct
systemat
review
agre
upon
recommend
safe
manag
prostat
cancer
patient
pandem
rad
framework
creat
remot
visit
avoid
defer
shorten
radiotherapi
appli
determin
appropri
approach
lowvolum
diseas
receiv
neoadjuv
hormon
therapi
month
necessari
ultrahypofraction
prefer
local
oligometastat
low
volum
moder
hypofraction
prefer
postprostatectomi
clinic
node
posit
diseas
salvag
prefer
adjuv
radiat
resourc
reduc
identifi
stage
prostat
cancer
rad
remot
visit
avoid
defer
shorten
radiotherapi
framework
appli
diseas
site
help
decis
make
global
pandem
cancer
treatment
era
requir
consider
risk
benefit
patient
staff
recent
data
suggest
patient
cancer
increas
risk
infect
seriou
complic
asco
provid
resourc
patient
receiv
system
therapi
http
wwwascoorgascocoronavirusinform
remain
minim
granular
guidanc
deliveri
outpati
radiotherapi
radiotherapi
deliv
nearli
cancer
patient
particularli
vulner
group
given
older
age
frequent
comorbid
underli
cancer
diagnosi
prostat
cancer
frequent
treat
radiat
common
solid
tumor
men
heterogen
diseas
time
therapi
indic
case
watch
wait
activ
surveil
deferr
treatment
could
accept
other
given
current
epidem
crisi
delay
radiotherapi
treatment
requir
multipl
visit
healthcar
facil
prostat
cancer
patient
may
potenti
reduc
risk
iatrogen
exposur
healthcar
system
level
clinic
appropri
reduc
visit
conserv
limit
hospit
resourc
eg
person
protect
equip
ppe
use
healthcar
worker
care
potenti
vast
number
hospit
patient
decis
delay
lifesav
cancer
treatment
time
resourceintens
pandem
repres
clinic
conundrum
without
modern
preced
exig
circumst
guidelin
manag
patient
present
prostat
cancer
would
valuabl
practic
clinician
manuscript
attempt
guidanc
base
rapid
expert
opinion
manag
prostat
cancer
patient
requir
radiotherapi
pandem
given
swiftli
evolv
clinic
knowledg
surround
potenti
impact
radiat
oncolog
depart
worldwid
perform
rapid
review
evid
assess
manag
local
prostat
cancer
radiat
therapi
goal
rapid
review
synthes
knowledg
provid
framework
clinic
practic
manag
prostat
cancer
pandem
framework
could
similarli
appli
resourc
constrain
set
diseas
type
within
framework
sought
answer
follow
key
question
achiev
assess
systemat
review
nation
guidelin
result
random
clinic
trial
treatment
arm
ongo
random
trial
assess
radiat
therapi
prostat
cancer
studi
requir
publish
english
januari
gener
recommend
follow
assumpt
made
pandem
last
multipl
month
often
occur
multipl
wave
variabl
peak
sever
pandem
signific
proport
staff
avail
work
eg
ill
quarantin
famili
respons
school
closur
capac
hospit
servic
exceed
stress
hospit
system
avail
staff
deploy
essenti
servic
ultim
combin
effect
resourc
stress
normal
workflow
possibl
rad
remot
visit
avoid
defer
shorten
radiotherapi
framework
develop
appli
prostat
cancer
diseas
state
commonli
treat
radiotherapi
figur
tabl
summar
group
recommend
diseas
stage
accord
visit
type
simul
fiduci
marker
rectal
spacer
placement
treatment
scenario
visit
procedur
treatment
safe
delay
variabl
durat
base
stage
diseas
visit
transit
telehealth
visit
video
visit
prefer
telehealth
visit
includ
simpl
phone
call
video
visit
possibl
given
limit
technolog
infrastructur
select
center
prostat
cancer
patient
requir
person
visit
pandem
minim
valu
digit
rectal
exam
less
risk
exposur
patient
staff
base
institut
resourc
legal
requir
ontreat
visit
also
perform
util
telehealth
technolog
reduc
exposur
risk
patient
must
seen
clinic
consider
given
patient
wait
car
outsid
facil
prior
appoint
promot
social
distanc
given
high
surfac
stabil
addit
number
visitor
patient
reduc
minimum
laboratori
test
eg
psa
test
perform
set
minim
contact
staff
patient
prefer
outsid
busi
hospit
set
possibl
routin
psa
test
posttreat
safe
defer
month
instanc
gener
low
low
favor
intermediaterisk
diseas
treatment
deferr
pandemicrel
restrict
lift
felt
safe
advic
base
multipl
clinic
trial
demonstr
patient
favor
outcom
watch
wait
activ
monitor
activ
surveil
reflect
nation
guidelin
recommend
broad
use
activ
surveil
lowand
lowrisk
prostat
cancer
select
use
favor
intermediaterisk
diseas
safeti
avoid
presum
pandem
wane
next
month
patient
unfavor
intermedi
high
highrisk
postprostatectomi
clinic
node
posit
oligometastat
low
volum
variabl
delay
inperson
new
patient
consult
return
visit
convert
time
remot
telehealth
visit
patient
initi
treatment
adt
allow
deferr
radiotherapi
necessari
base
natur
ongo
epidem
adt
ca
nt
deliv
eg
absolut
patient
refus
suppli
exhaust
toxic
adt
high
potenti
benefit
patient
rapid
psa
doubl
time
month
benefit
immedi
treatment
window
potenti
cure
must
weigh
exposur
subsequ
morbid
mortal
eg
age
comorbid
immunosuppress
adt
use
diseas
state
shown
deriv
surviv
benefit
low
low
favor
intermedi
risk
diseas
signific
prolong
adt
beyond
standardsofcar
avoid
given
potenti
increas
morbid
othercaus
mortal
agre
base
recent
present
evid
rave
radic
earli
salvag
radiotherapi
prefer
option
adjuv
radiotherapi
scenario
pandem
treatment
deem
necessari
safe
shortest
fraction
schedul
adopt
evid
safeti
efficaci
local
prostat
cancer
fraction
sbrtultrahypofraction
util
accord
nccn
guidelin
accept
regimen
intermediateand
highrisk
prostat
cancer
simplifi
schema
help
provid
perform
sbrt
shown
figur
center
without
abil
perform
imag
guidanc
conebeam
ct
without
fiduci
marker
fraction
regimen
util
gy
postprostatectomi
patient
moder
hypofraction
regimen
prefer
fraction
gy
low
volum
diseas
either
sbrt
gy
x
fraction
use
stamped
arm
h
safe
accept
dose
constraint
provid
supplementari
appendix
list
regimen
nonessenti
procedur
evid
support
impact
overal
surviv
rate
prostat
mri
fiduci
marker
andor
rectal
spacer
use
select
given
requir
either
prolong
extra
patient
visit
variabl
consid
deem
necessari
perform
prostat
sbrt
expedit
treatment
howev
prostat
sbrt
safe
perform
without
addit
procedur
necessari
eg
hypo
rt
pc
trial
use
conform
radiotherapi
larg
ctv
ptv
margin
use
rectal
spacer
mandat
mri
use
fiduci
marker
rectal
spacer
shown
reduc
rectal
toxic
recent
result
paceb
trial
demonstr
low
rate
rectal
toxic
without
use
rectal
spacer
thu
net
benefit
rectal
spacer
justifi
pandem
unless
simultan
place
fiduci
marker
local
anesthesia
unanim
consensu
treatment
need
perform
peak
pandem
brachytherapi
recommend
given
relianc
anesthesia
staff
ppe
howev
brachytherapi
perform
local
anesthesia
may
suitabl
option
experienc
method
resourc
avail
also
unanim
consensu
restrict
remov
radiotherapi
form
deliv
howev
import
still
cogniz
addit
wave
pandem
may
occur
restrict
reinstat
thu
util
shorter
cours
radiotherapi
may
still
necessari
review
discuss
use
palli
radiotherapi
often
necessarili
tumor
type
specif
eg
bone
metastas
spinal
cord
compress
bleed
etc
principl
rad
framework
appli
variabl
efficaci
palli
radiotherapi
weigh
risk
bring
patient
radiotherapi
altern
treatment
option
oral
analges
use
radiotherapi
avoid
treatment
may
caus
even
greater
exposur
surgeri
immunosuppress
system
therapi
prostat
cancer
common
cancer
men
worldwid
one
common
cancer
treat
within
radiat
oncolog
depart
proport
prostat
cancer
patient
receiv
radiotherapi
continu
expand
use
commonli
definit
treatment
local
local
advanc
diseas
adjuv
salvag
treatment
postsurgeri
oligometastat
direct
radiotherapi
treatment
primari
low
volum
metastat
diseas
furthermor
complex
treatment
prostat
cancer
increas
frequent
use
advanc
imag
includ
mri
molecular
pet
imag
imag
guidanc
fiduci
marker
rectal
spacer
requir
extra
procedur
visit
requir
extra
use
ppe
thu
prostat
cancer
patient
repres
import
popul
radiat
oncolog
depart
need
effici
manag
time
resourc
limit
prostat
cancer
patient
somewhat
uniqu
breast
cancer
prognosi
gener
favor
patient
aggress
diseas
use
adt
safe
delay
need
start
radiotherapi
multipl
month
reason
delay
radiotherapi
almost
alway
safe
prostat
cancer
also
uniqu
one
cancer
treat
cur
intent
radiotherapi
surviv
advantag
cancer
random
evid
singl
trial
demonstr
radiotherapi
improv
surviv
cancer
wors
prognosi
pancreat
cancer
radiotherapi
question
surviv
impact
thu
excess
delay
radiotherapi
aggress
prostat
cancer
patient
avoid
addit
although
adt
safe
use
extend
period
neoadjuvantli
must
recogn
prolong
cours
neoadjuv
adt
provid
oncolog
benefit
contribut
excess
morbid
even
mortal
thu
balanc
benefit
receiv
radiotherapi
larg
must
struck
impact
delay
treatment
start
small
excess
use
adt
variabl
risk
infect
morbiditymort
group
agre
although
variabl
level
evid
support
ultraand
moder
hypofraction
local
recurr
diseas
random
trial
demonstr
alter
field
size
fraction
extrem
doseescal
impact
overal
surviv
thu
set
pandem
mortal
possibl
shortest
safe
regimen
use
unlik
impact
longterm
surviv
cancer
recommend
formal
rule
polici
believ
possibl
data
limit
rather
goal
provid
guidanc
framework
think
numer
program
approach
care
patient
prostat
cancer
clinic
variou
stage
impact
restrict
global
pandem
recommend
follow
institut
state
feder
recommend
avail
best
manag
patient
practic
widmark
new
consult
return
visit
delay
necessari
base
resourc
avail
staff
abl
conduct
visit
without
impact
pandem
respons
resourc
continu
regular
schedul
use
remot
visit
psa
laboratori
test
defer
deem
safe
return
visit
delay
list
addit
delay
beyond
current
return
visit
interv
placement
fiduci
marker
rectal
spacer
requir
extra
ppe
use
benefit
procedur
base
resourc
staff
avail
brachytherapi
cautious
use
pandem
given
high
ppe
requir
resourc
util
avoid
gener
anesthesia
prefer
possibl
abbrevi
adt
androgen
depriv
therapi
fx
fraction
rt
radiotherapi
n
region
lymph
node
involv
fir
favor
intermedi
risk
uir
unfavor
intermedi
risk
rv
return
visit
ebrt
extern
beam
radiotherapi
